10.06.19|Hezi SternlichtFitch pins the downgrade on the drugmaker's slow revenue growth, persisting cost challenges and downward pressure on generic drug prices, and the company's legal trouble in the U.S.
22.07.18|Omri MilmanThe change was based on Israel’s favorable fiscal outcomes, strong institutional framework and on its “increasingly resilient economy”
22.02.18|Lilach BaumerMellanox has been embroiled in a control struggle with activist investor Starboard since the latter acquired a 10.7% stake in November and began pushing for operational and board reforms
08.11.17|Dror ReichThe company reported earnings of 1 cent per share, compared to analysts' expectations of 13 cents per share
More stories in CTech
